BSE Live
Apr 13, 16:01Prev. Close
576.10
Open Price
574.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 13, 15:47Prev. Close
578.10
Open Price
570.50
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
575.35 (140)
| Key Financial Ratios of Lincoln Pharmaceuticals (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 41.11 | 46.58 | 36.40 | 34.63 | 30.20 | |
| Diluted EPS (Rs.) | 41.11 | 46.58 | 36.40 | 34.63 | 30.20 | |
| Cash EPS (Rs.) | 47.55 | 51.89 | 40.97 | 38.66 | 33.04 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 335.34 | 295.98 | 250.86 | 216.12 | 182.48 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 335.34 | 295.98 | 250.86 | 216.12 | 182.48 | |
| Dividend / Share(Rs.) | 1.80 | 1.80 | 1.50 | 1.50 | 1.50 | |
| Revenue from Operations/Share (Rs.) | 311.15 | 289.84 | 254.78 | 235.69 | 206.53 | |
| PBDIT/Share (Rs.) | 61.89 | 67.07 | 55.74 | 52.66 | 44.06 | |
| PBIT/Share (Rs.) | 55.45 | 61.76 | 51.17 | 48.62 | 41.23 | |
| PBT/Share (Rs.) | 54.51 | 61.03 | 50.15 | 47.89 | 40.51 | |
| Net Profit/Share (Rs.) | 41.11 | 46.58 | 36.40 | 34.63 | 30.20 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 19.89 | 23.13 | 21.87 | 22.34 | 21.33 | |
| PBIT Margin (%) | 17.82 | 21.30 | 20.08 | 20.62 | 19.96 | |
| PBT Margin (%) | 17.51 | 21.05 | 19.68 | 20.32 | 19.61 | |
| Net Profit Margin (%) | 13.21 | 16.07 | 14.28 | 14.69 | 14.62 | |
| Return on Networth / Equity (%) | 12.25 | 15.73 | 14.50 | 16.02 | 16.55 | |
| Return on Capital Employed (%) | 16.07 | 20.34 | 19.89 | 21.93 | 22.12 | |
| Return on Assets (%) | 10.33 | 13.32 | 12.41 | 12.98 | 13.76 | |
| Total Debt/Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Asset Turnover Ratio (%) | 0.83 | 0.90 | 0.91 | 0.97 | 1.03 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 4.71 | 4.85 | 5.09 | 3.91 | 4.17 | |
| Quick Ratio (X) | 3.97 | 4.01 | 4.12 | 3.10 | 3.57 | |
| Inventory Turnover Ratio (X) | 8.00 | 7.89 | 2.48 | 2.80 | 2.45 | |
| Dividend Payout Ratio (NP) (%) | 4.37 | 3.22 | 4.12 | 4.33 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 3.78 | 2.89 | 3.66 | 3.87 | 0.00 | |
| Earnings Retention Ratio (%) | 95.63 | 96.78 | 95.88 | 95.67 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 96.22 | 97.11 | 96.34 | 96.13 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 1,082.75 | 1,160.22 | 646.55 | 606.63 | 437.02 | |
| EV/Net Operating Revenue (X) | 1.74 | 2.00 | 1.27 | 1.29 | 1.06 | |
| EV/EBITDA (X) | 8.73 | 8.64 | 5.79 | 5.75 | 4.96 | |
| MarketCap/Net Operating Revenue (X) | 1.77 | 2.02 | 1.33 | 1.32 | 1.09 | |
| Retention Ratios (%) | 95.62 | 96.77 | 95.87 | 95.66 | 0.00 | |
| Price/BV (X) | 1.64 | 1.98 | 1.35 | 1.44 | 1.23 | |
| Price/Net Operating Revenue | 1.77 | 2.02 | 1.33 | 1.32 | 1.09 | |
| Earnings Yield | 0.07 | 0.08 | 0.11 | 0.11 | 0.13 |
26.11.2025
Lincoln Pharma Consolidated September 2025 Net Sales at Rs 163.36 crore, up 1.33% Y-o-Y
24.11.2025
Lincoln Pharma Standalone September 2025 Net Sales at Rs 163.36 crore, up 1.33% Y-o-Y
07.08.2025
Lincoln Pharma Standalone June 2025 Net Sales at Rs 154.07 crore, up 4.61% Y-o-Y
24.06.2025
Lincoln Pharma Consolidated March 2025 Net Sales at Rs 168.18 crore, up 18.03% Y-o-Y
26.11.2025
Lincoln Pharma Consolidated September 2025 Net Sales at Rs 163.36 crore, up 1.33% Y-o-Y
24.11.2025
Lincoln Pharma Standalone September 2025 Net Sales at Rs 163.36 crore, up 1.33% Y-o-Y
07.08.2025
Lincoln Pharma Standalone June 2025 Net Sales at Rs 154.07 crore, up 4.61% Y-o-Y
24.06.2025
Lincoln Pharma Consolidated March 2025 Net Sales at Rs 168.18 crore, up 18.03% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth